Attaching Cell-Penetrating Peptides to Cancer Antibodies Boosts Internalization 4x and Cytotoxicity 6x | Research

The takeaway

Conjugating tetrameric cell-penetrating peptides to cancer antibodies increased their cellular internalization up to 4-fold and boosted the cytotoxicity of antibody-drug conjugate Kadcyla by 6-fold.

6x more cytotoxic
tCPP-modified Kadcyla was six times more effective at killing cancer cells than unmodified Kadcyla

What the researchers found

tCPP conjugation achieved up to 4-fold elevated internalization rates for three clinical antibodies while retaining target specificity. tCPP-Kadcyla showed 6-fold increased cytotoxicity. Favorable pharmacokinetics limited off-target accumulation.

Why it matters

Many antibody-drug conjugates underperform because they do not efficiently enter cancer cells. Boosting internalization with CPPs could make existing ADCs significantly more effective without developing entirely new drugs.

The numbers in context

4x internalization; 6x cytotoxicity for Kadcyla-tCPP; maintained specificity; improved PK; 3 antibodies tested

How the study worked

Solid-phase synthesis of tetrameric CPPs (tCPPs) conjugated to matuzumab, trastuzumab, and Kadcyla. Measured internalization rates, target specificity, pharmacokinetics, and cytotoxicity in cancer cell lines.

Who was studied

Cancer cell lines treated with tCPP-modified matuzumab, trastuzumab, and Kadcyla

What this study cannot tell us

In vitro only — in vivo efficacy and toxicity not assessed. Off-target effects of antigen-independent internalization need careful evaluation. Manufacturing scalability of tCPP-conjugated antibodies not addressed.

How to read the evidence

Preliminary — strong in vitro results with clinical antibodies but no in vivo validation of efficacy or safety.

When this study was published

Published in 2020; ADC engineering with enhanced internalization strategies continues to advance.

The bigger picture

This technology could be broadly applicable to the ADC drug class — a + billion market — by improving the intracellular delivery step that often limits their effectiveness.

Questions still open

Would the 6-fold cytotoxicity improvement translate to better tumor responses in animal models?
Does antigen-independent internalization cause off-target toxicity in vivo?
Can this approach be applied to other ADCs beyond Kadcyla?

Common questions

What are antibody-drug conjugates (ADCs)?

ADCs are cancer drugs that combine a targeting antibody (which finds cancer cells) with a cytotoxic payload (which kills them). The antibody delivers the drug directly to cancer cells, reducing side effects compared to traditional chemotherapy.

Why would adding cell-penetrating peptides help?

ADCs must enter cancer cells to release their toxic payload. Many ADCs are limited because they are not efficiently internalized. The tetrameric CPPs act like a molecular crowbar, dramatically increasing how quickly and how much antibody gets inside cancer cells.

Read the original research

Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery.

Journal of controlled release : official journal of the Controlled Release Society, 322, 200-208

View on PubMed ↗Publisher’s paper ↗

Citation

Sauter, Max; Strieker, Matthias; Kleist, Christian; Wischnjow, Artjom; Daniel, Volker; Altmann, Annette; Haberkorn, Uwe; Mier, Walter. (2020). Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery.. Journal of controlled release : official journal of the Controlled Release Society, 322, 200-208. https://doi.org/10.1016/j.jconrel.2020.03.005